Ömer Hazman, Ayşenur Sarıova, Mehmet Fatih Bozkurt, İbrahim Hakkı Ciğerci
Journal: Molecular and cellular biochemistry 2021;476(1):349-360
PMID: 32964394
Arbutin is one of the active ingredients employed in cosmetics as a skin whitening agent. In the present study, the possible effects of arbutin on breast cancer were determined with human breast adenocarcinoma (MCF-7) cells. α and β-arbutin cytotoxicity levels in MCF-7 cells were determined with the MTT method. At low (1-10 mM) doses, α-arbutin appears to be more toxic than β-arbutin. At higher (5-200 mM) and LD doses beta arbutin toxicity appears to be higher than alpha arbutin. Thus, the study was continued with β -arbutin. The effects of low and high doses of β-arbutin was determined on oxidative stress, genotoxicity, inflammation, apoptosis, proliferation, endoplasmic reticulum stress and estrogen receptor-α in MCF-7 cells. The results demonstrated that the β-arbutin doses administered to MCF-7 cells did not affect oxidative and endoplasmic reticulum stress in the experimental groups. However, it was found that administration of LD dose β-arbutin induced inflammation in these cells via proinflammatory cytokine levels (TNF-α, IFN-γ and IL-1β). It was observed that LD and LD doses of β-arbutin increased genotoxicity in MCF-7 cells. The gene expression analysis conducted with RT-PCR device and immunocytochemical analysis revealed that β-arbutin at LD dose induced apoptosis in MCF-7 cells via p53 and Caspase 3. Furthermore, it was determined that all β-arbutin doses inhibited estrogen receptor-α in MCF-7 cells. Considering that arbutin increased the activation of apoptotic Caspase 3 through p53, which was stimulated by genotoxic and inflammatory effects at LD dose in MCF-7 cells. Determination of this mechanism behind these effects of β-arbutin may contribute to the development of a new perspective in treatment.
Medical:
Miscellaneous:
Research Materials:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.